Clinical Scorecard: FDA Approves Baxdrostat for Resistant Hypertension
At a Glance
| Category | Detail |
|---|---|
| Condition | Resistant Hypertension |
| Key Mechanisms | Selective inhibition of aldosterone synthase, reducing aldosterone levels without affecting cortisol levels. |
| Target Population | Adults with uncontrolled hypertension despite treatment with at least two antihypertensive agents. |
| Care Setting | Outpatient clinical settings. |
Key Highlights
- First and only aldosterone synthase inhibitor approved for hypertension.
- Baxdrostat demonstrated significant reductions in systolic blood pressure in clinical trials.
- Approximately 50% of patients on multiple antihypertensive medications remain uncontrolled.
- Associated with a lower risk of serious cardiovascular events with a 10 mmHg decrease in systolic blood pressure.
- Under investigation for additional conditions including primary aldosteronism and chronic kidney disease.
Guideline-Based Recommendations
Diagnosis
- Evaluate patients with hypertension who are on multiple antihypertensive agents.
Management
- Consider baxdrostat for patients with resistant hypertension.
Monitoring & Follow-up
- Monitor blood pressure and aldosterone levels during treatment.
Risks
- Potential for persistent hypertension, cardiovascular disease, heart failure, and kidney disease if untreated.
Patient & Prescribing Data
Adults with resistant hypertension.
Baxdrostat has shown significant efficacy in reducing blood pressure in patients not responding to standard therapies.
Clinical Best Practices
- Incorporate baxdrostat into treatment plans for patients with resistant hypertension.
- Regularly assess blood pressure and adjust antihypertensive therapy as needed.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
